Literature DB >> 11090711

Immunoglobulin GM and KM allotypes and vaccine immunity.

J P Pandey1.   

Abstract

Immunoglobulin (Ig) GM and KM allotypes are genetic markers of gamma and kappa-type light chains, respectively. The striking qualitative and quantitative differences in the distribution of these determinants among different races raise questions concerning the nature of the evolutionary selective mechanism that maintains this variation. Associations between Ig allotypes and specific antibody responses could be a selective force for the maintenance of various haplotypes and their frequencies. Data from several studies reporting significant associations between certain GM and KM allotypes and immune responsiveness to polysaccharide vaccines and to particular infectious pathogens support this hypothesis. Possible ways in which constant (C)-region allotypes could contribute to the antibody specificity include the following: (i) certain alleles coding for allotypes may be in linkage disequilibrium with particular variable (V)-region determinants associated with immune responsiveness; (ii) they could directly contribute to the formation of specific idiotypes, as shown for the T15 system in mice; and (iii) allotype-associated structural variability in the C-region could modulate the kinetic competence of the antigen binding sites.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11090711     DOI: 10.1016/s0264-410x(00)00255-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Immunoglobulin KM genes in Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Christian A Vedeler
Journal:  Neurogenetics       Date:  2003-02-11       Impact factor: 2.660

2.  Immunoglobulin GM and KM genotypes in Korean patients with systemic lupus erythematosus.

Authors:  E B Lee; Y J Lee; D H Shin; Y M Choi; M H Park; J P Pandey; Y W Song
Journal:  Rheumatol Int       Date:  2006-08-31       Impact factor: 2.631

Review 3.  Human immunoglobulin allotypes: possible implications for immunogenicity.

Authors:  Roy Jefferis; Marie-Paule Lefranc
Journal:  MAbs       Date:  2009 Jul-Aug       Impact factor: 5.857

4.  Immunoglobulin GM and KM allotypes and prevalence of anti-LKM1 autoantibodies in patients with hepatitis C virus infection.

Authors:  Paolo Muratori; Susan E Sutherland; Luigi Muratori; Alessandro Granito; Marcello Guidi; Georges Pappas; Marco Lenzi; Francesco B Bianchi; Janardan P Pandey
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication.

Authors:  Raymond N Deepe; Emily Kistner-Griffin; Jeffrey N Martin; Steven G Deeks; Janardan P Pandey
Journal:  Hum Immunol       Date:  2011-12-11       Impact factor: 2.850

6.  Immunoglobulin KM allotypes are associated with the prevalence of autoantibodies to GD1a ganglioside, but not with susceptibility to the disease, in Japanese patients with Guillain-Barré syndrome.

Authors:  Janardan P Pandey; Michiaki Koga; Nobuhiro Yuki
Journal:  Neurogenetics       Date:  2005-10-29       Impact factor: 2.660

7.  Epistatic effects of immunoglobulin GM and KM allotypes on outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Jacquie Astemborski; David L Thomas
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies.

Authors:  Terrance P O'Hanlon; Lisa G Rider; Adam Schiffenbauer; Ira N Targoff; Karen Malley; Janardan P Pandey; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2008-10

Review 9.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

10.  Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody.

Authors:  H Marie Lacy; Melinda G Gunnell; Elizabeth M Laurenzana; S Michael Owens
Journal:  Int Immunopharmacol       Date:  2007-10-23       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.